Chosa Oncology News and Activities

Chosa Oncology is a company listed under the stock ticker RHOVAC (SE).

View the org chart displaying its 7 main executives

Most searched biographies at Chosa Oncology

• Peter Buhl, Chief Executive Officer
• Morten Myrhøj, Director
• Ingrid Atteryd Heiman, Chairman of the Board

Popular executive movements at Chosa Oncology

• William Cronin has joined the company as Head of US Business Development and Commercialization  (posted on July 13 2026).

Create your alert
to follow the executive moves at Chosa Oncology.

Chosa Oncology has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Chosa Oncology

• CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP - CHOSA Oncology
• CHOSA utser Bill Cronin, med ett bred erfarenhet av onkologimarknaden, att leda den amerikanska kommersialiseringen för att accelerera lanseringen av Platin-DRP - CHOSA Oncology
• CHOSA Oncology announces commencement of exercise period for TO2 warrants at the fixed price of SEK 0.78 - CHOSA Oncology
• CHOSA Oncology meddelar att teckningsperioden för TO2-teckningsoptioner inleds till det fastställda lösenpriset om 0,78 SEK - CHOSA Oncology
• CHOSA Oncology etablerar närvaro i USA för att stödja kommersialiseringen av Platin-DRP - CHOSA Oncology
• CHOSA Oncology establishes US presence in Boston to support commercialization of Platin-DRP - CHOSA Oncology
• CHOSA and AIDA present data at ASCO 2026 showing up to 78% pathological complete response (pCR) rate in breast cancer using combined, integrated, taxane and platinum biomarkers - CHOSA Oncology
• CHOSA presents data at ASCO validating Platin-DRP on the NanoString platform showing significant overall survival prediction in Phase III lung cancer study - CHOSA Oncology
• CHOSA presenterar data vid ASCO som validerar Platin-DRP på NanoString-plattformen och visar signifikant prediktion av total överlevnad i en fas III-studie inom lungcancer - CHOSA Oncology
• CHOSA och AIDA presenterar data vid ASCO 2026 som visar upp till 78 % patologisk komplett respons (pCR) vid bröstcancer med hjälp av kombinerade, integrerade biomarkörer för taxan och platin - CHOSA Oncology
• View more press releases Close

Social media about Chosa Oncology

• Chosa Oncology on Wikipedia, Google News & Yahoo Finance
• Chosa Oncology on LinkedIn, X (Twitter) & YouTube